Equine anti-doping analysis is a changing and dynamic field of science. The constant introduction of new drugs and biopharmaceuticals present challenges to the integrity of sports. Anti-doping programs are continually falling under fire due to allegations of perceived doping by athletes with drugs that are rumored to be undetectable by the current testing schemes which in some cases offer limited drug coverage. The continual advancements of modern mass spectrometry, specifically, the Orbitrap MS have enabled anti-doping laboratories to significantly expand the drug coverage for both human and equine athletes. Both the benchtop Exactive and the Q Exactive Orbitrap mass spectrometers have been used by the K.L. Maddy Equine Analytical Chemistry Laboratories at UC Davis for the past six years. The Q Exactive's improved sensitivity combined with its enhanced MS/MS capabilities make it an outstanding tool for anti-doping labs. The Q Exactive is combined with a high pressure liquid chromatograph system which facilitate the sample throughout and aids in compound separation. The fast scan speed and high resolution capability enables the detection of both small and large molecules in a single analytical run. In addition, the Q Exactive readily detects larger conjugated drugs and small peptide drugs extracted from a biological matrix. The Orbitrap method coverage exceeds 600 compounds, including Phase I and Phase II drug metabolites. The rapid cycle time allows for analysis of >100 samples per instrument per day. This approach has been successfully employed and the return on investment was calculated at ~15 months.
Who Should Attend:
• Anti-doping laboratory managers, supervisors & chemists
• Bio-analytical laboratory managers, supervisors & chemists
• Toxicology laboratory managers, supervisors & chemists
• Equine testing laboratory managers, supervisors & chemists
Key Learning Objectives:
• Expanded drug coverage for anti-doping labs
• Detection of both small and large molecules in a single analytical run
• Detection of > 600 compounds, including phase I and phase II drug metabolites
• Analysis of >100 samples per instrument per day